# Abionyx Pharma

Abionyx Pharma is an Asset Manager based in Balma, France.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Balma, France
- **Region:** Europe
- **Address:** 33 av. Georges Pompidou, Bât. D, 31130 Balma, France
- **Assets under management:** Undisclosed
- **Website:** abionyx.com
- **LinkedIn:** https://www.linkedin.com/company/abionyx

## Regulatory record

- **Reports private funds:** No

## About

Abionyx is a biotech company engaged in the discovery and development of therapies for patients without existing or effective treatment. It plans to explore joint activities with partners.

## Sectors

- Biotechnology
- Renal Disease
- Ophthalmology
- Sepsis
- Inflammation

## Questions

### What is Abionyx Pharma's therapeutic focus?

Abionyx Pharma targets renal and ophthalmological diseases with no existing or effective treatment. Its core scientific asset is recombinant apolipoprotein A-I (apoA-I), which it engineers both as a direct therapeutic and as part of HDL vectors for targeted drug delivery. The firm's lead clinical programs are concentrated in sepsis-associated acute kidney injury, leveraging data from the RACERS study published in BMC Medicine / Nature Springer (per firm website, 2025). This dual therapeutic and delivery platform approach is rare among publicly listed European biotechs.

### Who runs investment and strategic decisions at Abionyx Pharma?

Abionyx Pharma is structured as a publicly listed biotech company operating through a General Assembly governance model. Strategic and investment decisions are made by management within the framework of shareholder-approved mandates; the firm's website does not currently list named executives on its team page or disclose individual investment authority. The most recent General Assembly took place in June 2025 (per firm website). Specific decision-maker names were not verifiable from available sources.

### What is the significance of the March 2026 biomanufacturing milestone?

In March 2026, Abionyx announced a breakthrough in synthetic sphingomyelin production, a critical component for biomanufacturing its apoA-I-based HDL therapies (per firm press release, March 2026). Sphingomyelin stabilization is essential for scalable, consistent production of recombinant HDL particles. This advancement reduces a key supply-chain bottleneck and increases the likelihood of advancing lead HDL candidates into later-stage clinical trials or partner discussions.

## Related profiles

- [Aberle Investment Management](https://altss.com/profile/aberle-investment-management-llc)
- [ABUI Capital](https://altss.com/profile/abui-capital)

---

Last updated: 2026-07-11T16:12:08.000Z

Canonical page: https://altss.com/profile/abionyx-pharma

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology